Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 23, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 5, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 5, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,34818 flagged findings
Reported transactions (Form 4)80since Feb 11, 2025 · and 31 other holdings
Corporate events (8-K)30since Apr 21, 2022
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-08-05share offering or dilution eventfreshOpen filing ↗“…number of our common stock in the public market, including sales by members of our management or board of directors, or the…”
+1 more passage from the same document
- “…securities are adjusted if the issuers were to issue similar or identical securities or when there is a triggering event for…”
- 2026-08-05capital return (buybacks/dividends)freshOpen filing ↗“…of the $100.0 million of the first DM1 Milestone, costs incurred as a result of the partial refinancings of the 2027 Notes in…”
+1 more passage from the same document
- “…the $100.0 million of the first DM1 Milestone, costs incurred as a result of the partial refinancings of the 2027 Notes in August and…”
- 2026-08-05Department of Justice inquiryfreshOpen filing ↗“…enforcement approach is unclear but may impact pharmaceutical marketing efforts industry-wide, including for us, which could in turn…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 1,348)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 23, 268-K ↗Current report · Entered a material agreement
- Aug 13, 26SCHEDULE 13G/A ↗Passive stake · AQR Capital Management, LLC · 5.0% · event on Jun 30, 26 · amendment
- Aug 7, 26SCHEDULE 13G ↗Passive stake · STATE STREET CORPORATION · 8.4% · event on Jun 30, 26
- Aug 5, 268-K ↗Current report · Results
- Aug 5, 2610-Q ↗Quarterly report
- Jul 31, 26SCHEDULE 13G/A ↗Passive stake · Vanguard Portfolio Management · 8.1% · event on Jun 30, 26 · amendment
- Jul 30, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 15.8% · event on Jun 30, 26 · amendment
- Jul 29, 26Form 4 ↗Insider transaction
- Jul 29, 26Form 3 ↗Insider transaction
- Jul 27, 268-K ↗Current report · A senior executive left or was appointed
Insider transaction · 8 Form 4 filingsshow all 8hide
- Jun 4, 268-K ↗Current report · A senior executive left or was appointed
- May 6, 268-K ↗Current report · Results
- May 6, 2610-Q ↗Quarterly report
1,348 filings on record, the oldest from Jul 9, 97.
Listing the 25 most recent filings of the 1,348 on record.
67976
- Sep 23, 26Entered a material agreement8-K 1.01 ↗
3 senior executive changes2026show all 3hide
- Jul 27, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 4, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Feb 25, 26A senior executive left or was appointed8-K 5.02 ↗
- Dec 19, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Dec 11, 25Sold unregistered shares+2 more in the same filing8-K 3.02 ↗
- Dec 8, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Aug 29, 25Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Aug 21, 25Sold unregistered shares8-K 3.02 ↗
- Aug 13, 25A senior executive left or was appointed8-K 5.02 ↗
- Jul 16, 25Restructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
- Jun 6, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Feb 14, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Nov 26, 24Entered a material agreement8-K 1.01 ↗
8 older filings not shown · The record reaches back to Jan 20, 05.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Mar 8, 16Restructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗
- Jun 1, 12Listing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
- Dec 14, 11Listing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
- Dec 13, 11Restructuring plan with committed costs8-K 2.05 ↗
- Oct 24, 07Past accounts declared unreliable and being restated+1 more in the same filing8-K 4.02 ↗
The full record holds 6 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.15.8%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
- The Vanguard Group10.9%Aug 29, 25SCHEDULE 13G/A ↗
- STATE STREET CORPORATION8.4%Jun 30, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Vanguard Portfolio Management8.1%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
- Vanguard Capital Management5.1%Mar 31, 26SCHEDULE 13G ↗
show 3 more holdershide
- AQR Capital Management, LLC5.0%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- D. E. Shaw & Co., L.P.1.9%Sep 30, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- Capital International Investors0.5%Jun 30, 25SCHEDULE 13G/A ↗
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
- Mar 12, 26Sell$123KStephen Mayo↗
Stock compensation, tax and giftsshow the 39 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 4, 26Tax$476KLouise Rodino-KlapacPresident, R&D and Tech Ops↗
- Sep 4, 26Tax$489KCristin RothfussEVP, General Counsel↗
- Sep 4, 26Tax$551KIan Michael EstepanChief Operating Officer↗
- Sep 4, 26Tax$295KRyan Ho-Yan WongChief Financial Officer↗
- Jul 28, 26Compensationamount n/aMICHAEL SEVERINOChief Executive Officer↗
- Jun 4, 26Compensationamount n/aRichard Barry↗
- Jun 4, 26Compensationamount n/aMichael Andrew Chambers↗
- Jun 4, 26Compensationamount n/aClaude Nicaise↗
- Jun 4, 26Compensationamount n/aDeirdre P Connelly↗
- Jun 4, 26Compensationamount n/aM KATHLEEN BEHRENS↗
- Jun 4, 26Compensationamount n/aHans Lennart Rudolf Wigzell↗
- Jun 4, 26Compensationamount n/aStephen Mayo↗
- Jun 4, 26Compensationamount n/aKathryn Jean Boor↗
- Mar 11, 26Tax$17KCristin RothfussEVP, General Counsel↗
- Mar 11, 26Tax$16KLouise Rodino-KlapacPresident, R&D and Tech Ops↗
- Mar 11, 26Tax$4KRyan Ho-Yan WongChief Financial Officer↗
- Mar 11, 26Tax$19KIan Michael EstepanChief Operating Officer↗
- Mar 9, 26Tax$18KIan Michael EstepanChief Operating Officer↗
- Mar 9, 26Tax$10KIan Michael EstepanChief Operating Officer↗
- Mar 9, 26Tax$9KLouise Rodino-KlapacPresident, R&D and Tech Ops↗
- Mar 9, 26Tax$15KLouise Rodino-KlapacPresident, R&D and Tech Ops↗
- Mar 9, 26Tax$8KCristin RothfussEVP, General Counsel↗
- Mar 9, 26Tax$6KCristin RothfussEVP, General Counsel↗
- Mar 9, 26Tax$3KRyan Ho-Yan WongChief Financial Officer↗
- Mar 9, 26Tax$2KRyan Ho-Yan WongChief Financial Officer↗
- Mar 2, 26Tax$60KLouise Rodino-KlapacPresident, R&D and Tech Ops↗
- Mar 2, 26Tax$12KLouise Rodino-KlapacPresident, R&D and Tech Ops↗
- Mar 2, 26Tax$53KIan Michael EstepanChief Operating Officer↗
- Mar 2, 26Tax$14KIan Michael EstepanChief Operating Officer↗
- Mar 2, 26Tax$7KRyan Ho-Yan WongChief Financial Officer↗
- Mar 2, 26Tax$7KCristin RothfussEVP, General Counsel↗
- Mar 1, 26Compensationamount n/aLouise Rodino-KlapacPresident, R&D and Tech Ops↗
- Mar 1, 26Compensationamount n/aIan Michael EstepanChief Operating Officer↗
- Feb 26, 26Compensation$28KIan Michael EstepanChief Operating Officer↗
- Feb 26, 26Compensation$74KIan Michael EstepanChief Operating Officer↗
- Jan 29, 26Compensation$144KClaude Nicaise↗
- Jan 29, 26Tax$144KClaude Nicaise↗
- Jan 27, 26Compensation$144KM KATHLEEN BEHRENS↗
- Jan 27, 26Tax$144KM KATHLEEN BEHRENS↗
The full record holds 239 transactions and goes back to Dec 31, 22.
Its sector and its market
Sarepta Therapeutics Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Sarepta Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Sarepta Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 1,348 documents on file, from Jul 9, 1997 to Sep 23, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.